Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: A two-year randomised controlled trial

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 106, Issue 7, 1999, Pages 678-683

  Beardsworth, S A ^a   Kearney, C E ^a   Purdie, D W ^a  

^a HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TIBOLONE;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; HEADACHE; HOT FLUSH; HUMAN; LUMBAR SPINE; MASTALGIA; MUSCLE WEAKNESS; OBESITY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VAGINA BLEEDING; VAGINA DISCHARGE;

ANABOLIC AGENTS; BONE DENSITY; DENSITOMETRY, X-RAY; FEMALE; FEMUR; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0032972664     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1999.tb08367.x     Document Type: Article

References (26)

1. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet 1976; 1: 1038–1041.
2. Grady D, Rubin SM, Petitti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 1992; 81: 3829–3838.
3. Tang MX, Jacobs D, Stem Y et al. Effect of oestrogen during menopause at risk and age of onset of Alzheimer’s disease. Lancet 1996; 348:429–432.
4. Femandez E, La Vecchia C, D’Avanzo B et al. Oral contraceptives, hormone replacement therapy and the risk of colorectal cancer. Er J Cancer 1996; 73: 1431–1435.
5. Hales AM, Chamberlain CG, Murphy CR, McAvoy JW. Oestrogen protects lenses against cataract induced by transforming growth factor-beta. J Exp Med 1997; 185: 273–280.
6. Paavonen T. Hormonal regulation of immune responses. Ann Med 1994; 26: 255–258.
7. Purdie DW, Steel SA, Howey S, Doherty SM. The technical and logistical feasibility of population densitometry using DXA and directed HRT intervention: A two-year prospective study. Osteoporosis Int 1996; 11: S31–S36.
8. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–1059.
9. Fotherby K. Metabolism of synthetic steroids by animal and man. In: Briggs MH, Diczfalusy E, editors. Meeting on pharmacological models to assess toxicity and side effects of fertility regulating agents. Geneva, September 1973: 17–17.
10. Crona N, Samsioe G, Lindberg UB, Silfverstolpe G. Treatment of climacteric complaints with Org OD 14 a comparative study with oestradiol valerate and placebo. Maturitas 1988; 9: 303–308.
11. Genazzani AR, Benedek-Jaszmann LJ, Hart DM, Andolsek L, Kicovic PM, Tax L. Org OD 14 and the endometrium. Maturitas 1991; 13: 243–251.
12. Kloosterboer HJ, Benedek-Jaszmann LJ, Kicovic PM. Long term effects of Org OD 14 on lipid metabolism in postmenopausal women. Mafuritas 1990; 12: 37–42.
13. Rymer J, Crook D, Sidhu M, Chapman M, Stevenson JC. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol 1993; 128: 259–262.
14. Bjamason NH, Bjamason K, Haarbo J, Coelingh Bennink HJT, Christiansen C. Tibolone: Influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997; 82: 1752–1756.
15. Chetrite G, Kloosterboer HJ, Pasqualini JR. Effect of tibolone (Org OD 14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 1997; 17: 135–140.
16. Kloosterboer HJ, Schoonen WGEJ, Deckers GH, Klijn JGM. Effects of progestogens and Org OD 14 in in-vitro and in-vivo tumour models. J Steroid Biochem Molec Eiol 1994; 49: 311–318.
17. Lindsay R, Hart DM. Kraszewski A. Prospective double blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. EMJ 1980; 185:1207–1209.
18. Beming B, Kuijk CV, Kuiper JW, Coelingh Bennink HJT, Kicovic PM, Fauser BUM. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: A two-year randomised, placebcontrolled study. Bone 1996; 19: 395–399.
19. Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int 1994; 4: 314–319.
20. Bjamason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C. Tibolone: Prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996; 81: 2419–2422.
21. Prelevic GM, Bartram C, Wood J, Okola S, Ginsburg J. Comparative effects on bone mineral density of tibolone, transdermal oestrogen and oral oestrogedprogestogen therapy in postmenopausal women. Gynecol Endocrinol 1996; 10: 413–420.
22. Lippuner K, Haenggi W, Bukhaeuser MH, Jaeger P. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17–oestradiol and dydrogesterone. J Bone Miner Res 1997; 12: 806–812.
23. Ederveen AGH, Kloosterboer HJ. The protective effect of tibolone on ovariectomy induced bone loss is blocked by an anti-oestrogen. Proceedings of The First Amsterdam Menopause Symposium, April 13, 1998.
24. Naessen T, Persson I, Ljunghall S, Bergstrom R. Women with climacteric symptoms: A target group for prevention of rapid bone loss and osteoporosis. Osteoporosis Int 1992; 2: 225–231.
25. Ederveen AGH, Spanjers CPM, Quaijtaal JHM, Kloosterboer HJ. Biomechanical properties of cortical and trabecular bone after tibolone or EE treatment of mature ovariectomised rats. Osteoporosis Int 1996; 6(Suppl1):210.
26. Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73–79.